Sana Biotechnology (NASDAQ:SANA) Trading Up 7.8% – Time to Buy?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares shot up 7.8% on Friday . The stock traded as high as $3.30 and last traded at $3.3310. 939,320 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 2,337,721 shares. The stock had previously closed at $3.09.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on SANA shares. Zacks Research lowered shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 3rd. Morgan Stanley reissued an “overweight” rating and issued a $12.00 price objective on shares of Sana Biotechnology in a report on Friday. HC Wainwright cut their price objective on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, March 4th. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Finally, Bank of America lifted their target price on Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Sana Biotechnology Trading Up 8.7%

The firm has a market cap of $896.68 million, a price-to-earnings ratio of -3.46 and a beta of 1.96. The stock has a 50-day moving average of $4.16 and a 200-day moving average of $4.13.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Trading of Sana Biotechnology

Hedge funds have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its holdings in Sana Biotechnology by 4.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock worth $188,000 after buying an additional 2,023 shares in the last quarter. Xponance LLC raised its stake in Sana Biotechnology by 25.6% during the 4th quarter. Xponance LLC now owns 13,068 shares of the company’s stock valued at $53,000 after acquiring an additional 2,662 shares in the last quarter. Creative Planning boosted its position in Sana Biotechnology by 5.3% during the 3rd quarter. Creative Planning now owns 54,177 shares of the company’s stock worth $192,000 after acquiring an additional 2,719 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Sana Biotechnology by 29.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company’s stock worth $53,000 after purchasing an additional 2,943 shares in the last quarter. Finally, Savant Capital LLC grew its stake in shares of Sana Biotechnology by 5.6% in the third quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock worth $236,000 after purchasing an additional 3,500 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.